Moderna
Moderna Stock Surges 126% After Cancer Vaccine Trial Success
Moderna shares surged more than 120% on Wednesday, sending the biotechnology company’s stock to what could become its strongest trading day ever after...
FDA Clears First mRNA Flu Vaccine for Adults 50 and Older
The U.S. Food and Drug Administration has approved the nation’s first mRNA-based influenza vaccine for adults aged 50 and older, marking a major...
Stéphane Bancel: Leading Moderna’s Evolution and Innovation
Stéphane Bancel, born on July 20, 1972, in Marseille, France, has emerged as a pivotal figure in the biotechnology sector. Currently serving as...
Moderna Stock Plunges as Company Slashes 2025 Revenue Forecast and Announces Major Cost Cuts
Moderna (NASDAQ: MRNA) shares tumbled 18% in premarket trading on Monday after the biotechnology company significantly lowered its 2025 revenue forecast and announced...
Stéphane Bancel: The Visionary Leader Behind Moderna’s Revolution
Stéphane Bancel is one of the most transformative figures in modern biotechnology, known for his pivotal role as the CEO of Moderna, the...
Moderna’s Combo COVID-Flu Vaccine Promising in Trials
Moderna recently announced promising results from its late-stage trial of a combination COVID-19 and flu vaccine. The study revealed that the combination shot...
FDA Panel Backs New COVID Vaccines for JN.1 Variant by Fall
An expert panel from the Food and Drug Administration (FDA) voted unanimously on Wednesday to develop new COVID-19 vaccines specifically targeting the JN.1...
